Search

Your search keyword '"S. I. Glukhova"' showing total 213 results

Search Constraints

Start Over You searched for: Author "S. I. Glukhova" Remove constraint Author: "S. I. Glukhova"
213 results on '"S. I. Glukhova"'

Search Results

1. Multifunctional protein nucleobindin 1 as a marker of vascular damage in systemic lupus erythematosus

2. Assessment of the damage index and its dynamics in patients with non-systemic variants of juvenile arthritis during the treatment with biologics

3. Comparative characteristics of axial spondyloarthritis and psoriatic arthritis with axial involvement

4. 7 year of sacroiliac radiographic progression in early psoriatic arthritis (preliminary results)

5. Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)

6. Evaluation of the impact of a course of therapy with an injectable form of chondroitin sulfate on the duration of remission and quality of life in patients with osteoarthritis

7. Factors associated with achieving an acceptable health-related quality of life in the treatment of patients with psoriatic arthritis

8. Search for predictors of achieving minimal disease activity during tofacitinib therapy in patients with psoriatic arthritis

9. Adverse events that occurred in patients with rheumatoid arthritis during long-term follow-up

10. Prognostic factors associated with non-remission and low disease activity status af ter one year of psoriatic arthritis patients treatment in real practice

11. Clinical and immunologic features of the phenotype of systemic lupus erythematosus combined with Sjögren's syndrome

12. Comorbid infections in patients with spondyloarthritis: frequency, structure and risk factors

13. Evaluation of the possibility of axial psoriatic arthritis patients meet classification criteria for axial spondyloarthritis and ankylosing spondylitis

14. The use of 'Acellbia' – a biosimilar of rituximab in systemic sclerosis

15. The use of the combined vector vaccine GamCOVID-Vac (Sputnik V) in patients with immuno-inflammatory rheumatic diseases: safety issues-news

16. Safety and tolerability of rituximab in the treatment of systemic sclerosis

17. Lupus nephritis as a specific clinical and immunological phenotype of systemic lupus erythematosus

18. 2-years outcomes of the treat-to-target strategy in early psoriatic arthritis

19. Clinical and immunological phenotypes of systemic lupus erythematosus, identified based on cluster analysis of data from 400 patients from V.A. Nasonova Research Institute of Rheumatology

20. Comorbid infections in patients with spondyloarthritis who received modern antirheumatic therapy (preliminary data)

21. Clinical and instrumental characteristics of axial involvement in psoriatic arthritis in real-life clinical practice

22. Analysis of the relationship between the response to methotrexate therapy and its pharmacokinetic parameters in rheumatoid arthritis. Sovremennaya Revmatologiya

23. Contributing factors of diabetes mellitus among patients with gout (results of the long-term prospective study)

24. Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus

25. Ovarian reserve in patients with systemic sclerosis

26. Analysis of 5-year clinical and radiological outcomes in patients with psoriatic arthritis observed as part of the Treat to target strategy. Preliminary data

27. Results of an open multicenter non-interventional study of clinical efficacy and tolerability of etoricoxib in osteoarthritis and nonspecific back pain with additional evaluation of the effect of the drug on the «central» manifestations of pain

28. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

29. Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study

30. Analysis of the factors determining the development of postoperative pain in patients after knee and hip replacement surgery

31. Determination of the accuracy of osteoporotic fractures risk assessment in patients with rheumatoid arthritis using the prognostic model, developed at V.A. Nasonova Research Institute of Rheumatology, and the FRAX algorithm

32. Prognostic factors associated with achieving minimal disease activity in early psoriatic arthritis patients treated according to 'treat-to-target' st rategy within 12 months

33. Treatment of ankylosing spondylitis during pregnancy

34. Significance of asymptomatic hyperuricemia in ankylosing spondylitis

35. Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients

36. Prevalence and risk f actors influencing the development of arterial hypertension in patients with a gout

37. The neutrophil-to-lymphocyte ratio in complete blood cell count may be an available marker for active adult-onset Still's disease

38. Therapeutic drug monitoring of methotrexate and its metabolites in the red blood cells and mononuclear cells of patients with rheumatoid arthritis

39. Assessment of Ankylosing Spondylitis Activity During Pregnancy Using Different Disease Activity Indices

40. Possibilities of screening for a high-risk axial skeletal lesion in psoriatic arthritis

41. Specific features of axial involvement in psoriatic arthritis: data from real clinical practice

42. Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab

43. Panniculitis in modern rheumatology

44. Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up

45. Depression and severity of articular destruction in patients with rheumatoid arthritis

46. Efficacy and safety of two 'Carmolis' forms for combined local therapy of knee osteoarthritis: results of a multicenter clinical trial

47. NEUROPSYCHIATRIC DISORDERS IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A RETROSPECTIVE STUDY

48. Evaluation of the modified combined glucocorticoid toxicity index in rheumatoid arthritis: Preliminary data

49. Analysis of peripheral blood parameters for the diagnosis of inflammatory activity in rheumatoid arthritis

50. Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis

Catalog

Books, media, physical & digital resources